Haemonetics breaks OrthoPAT contract with Zimmer in US
This article was originally published in Clinica
In a move to advance revenue growth and create "greater shareholder value", Haemonetics is to sell its OrthoPAT surgical blood salvage system through its direct sales force in the US, effective immediately.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.